The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

8125658114158064805a8f8a6d-cb94-403f-8568-5ecf1acf88d58f31fd07-f2ab-4fbc-a61f-4ceb845956f8df73e933-0850-4d45-b115-ad2c4ba43be5ARGS_News_2015_2_27_General_Releases.pdfARGS_News_2015_2_24_General_Releases.pdfARGS_News_2015_2_2_General_Releases.pdf1739017052143241232015-2-27T8:30:0-5:02015-2-24T8:30:0-5:02015-2-2T16:30:0-5:0898870897956894187General ReleasesGeneral ReleasesGeneral ReleasesPrincipal Investigator Dr. Robert Figlin to Provide Updates on Phase 2 AGS-003 Plus Sunitinib Experience and Highlight Progress for Ongoing ADAPT Phase 3 TrialArgos Therapeutics Announces Update on Phase 3 ADAPT Trial to be Presented During 2015 ASCO Genitourinary Cancers SymposiumJoan C. Winterbottom Joins Argos Therapeutics as Chief Human Resources OfficerArgos Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference848484201520152015No Error0

Argos Therapeutics Announces Update on Phase 3 ADAPT Trial to be Presented During 2015 ASCO Genitourinary Cancers Symposium
Read more

Joan C. Winterbottom Joins Argos Therapeutics as Chief Human Resources Officer
Read more

Argos Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference
Read more

> More News & Events Here.

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC